financetom
Business
financetom
/
Business
/
Japan's Tokyo Gas expands in US shale gas with Chevron deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Japan's Tokyo Gas expands in US shale gas with Chevron deal
Mar 31, 2025 7:30 PM

TOKYO (Reuters) - TG Natural Resources LLC (TGNR), co-owned by Tokyo Gas ( TKGSF ) and Castleton Commodities International, has bought a 70% stake in the east Texas gas assets from Chevron ( CVX ) for $525 million, the company said on Tuesday, as it expands its U.S. gas business.

TGNR is already the fourth biggest producer in the Haynesville shale basin and the deal would allow to realize synergies of over $170 million during the asset's development, Craig Jarchow, the company's chief executive, said in a statement.

Haynesville's location in east Texas and northwest Louisiana is ideal for exports from liquefied natural gas (LNG) facilities and projects clustered on the nearby Gulf Coast, and has investors' attention as U.S. President Donald Trump aims to boost gas exports.

Tokyo Gas ( TKGSF ), Japan's largest city gas provider, said last week it wanted to increase coordination between its LNG trading and shale gas businesses in the U.S. and expand there, as it sees shale gas as a major profit pillar in the coming years.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biogen's Leqembi Has 'Meaningful Advantages' Over Lilly's Kisunla, Leading to Potential Billions in Sales, RBC Says
Biogen's Leqembi Has 'Meaningful Advantages' Over Lilly's Kisunla, Leading to Potential Billions in Sales, RBC Says
Jun 27, 2025
08:33 AM EDT, 06/27/2025 (MT Newswires) -- Biogen's (BIIB) potential Alzheimer's disease drug Leqembi has meaningful advantages over Eli Lilly's ( LLY ) Kisunla that could help surpass its rival, RBC Capital Markets said in a note to investors on Friday. While Kisunla is being developed and tested more quickly, Leqembi's subcutaneous administration and cleaner safety could help it gain...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Nike's Q4 Sales Beat Points to Modest Recovery Amid Margin Pressures, Morgan Stanley Says
Nike's Q4 Sales Beat Points to Modest Recovery Amid Margin Pressures, Morgan Stanley Says
Jun 27, 2025
08:33 AM EDT, 06/27/2025 (MT Newswires) -- Nike ( NKE ) is positioned for a cautious recovery as its fiscal Q4 sales modestly outperformed expectations across most regions except China, Morgan Stanley said in a note Friday. Nike ( NKE ) reported fiscal Q4 revenues of $11.1 billion, down 12% year-over-year, but both revenue and earnings per share of $0.14...
Schrodinger Drug Gets FDA Fast Track for Rare Blood Cancer Treatment
Schrodinger Drug Gets FDA Fast Track for Rare Blood Cancer Treatment
Jun 27, 2025
08:35 AM EDT, 06/27/2025 (MT Newswires) -- Schrodinger (SDGR) said Friday the US Food and Drug Administration has granted fast track designation to SGR-1505 for treating relapsed or refractory Waldenstrom macroglobulinemia, a rare form of blood cancer. The treatment targets adult patients who have failed at least two prior therapies, including a Bruton's tyrosine kinase inhibitor, the company said. SGR-1505...
Copyright 2023-2026 - www.financetom.com All Rights Reserved